OCREVUS's safety and efficacy for PPMS were studied in over 700 patients.

The ORATORIO trial for PPMS 4,42

The efficacy and safety of OCREVUS (ocrelizumab) for PPMS were studied in over 700 patients in a placebo-controlled trial.

OCREVUS® (ocrelizumab) has demonstrated effectiveness in PPMS

Demonstrated effectiveness in PPMS 4,42

OCREVUS was proven in PPMS across key clinical and MRI measures of efficacy and safety.

More than six years of OCREVUS® (ocrelizumab) safety data

OCREVUS safety profile for PPMS 2-4

The safety of OCREVUS for PPMS was studied in the >2-year ORATORIO clinical trial and and observed in over 4 years of open-label extension study.

PPMS=primary progressive multiple sclerosis.